CA2478082C - Utilisations d'anticorps 8h9 monoclonaux - Google Patents
Utilisations d'anticorps 8h9 monoclonaux Download PDFInfo
- Publication number
- CA2478082C CA2478082C CA2478082A CA2478082A CA2478082C CA 2478082 C CA2478082 C CA 2478082C CA 2478082 A CA2478082 A CA 2478082A CA 2478082 A CA2478082 A CA 2478082A CA 2478082 C CA2478082 C CA 2478082C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- tumor
- cells
- cell
- tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- QRMPKOFEUHIBNM-UHFFFAOYSA-N CC1CCC(C)CC1 Chemical compound CC1CCC(C)CC1 QRMPKOFEUHIBNM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Abstract
L'invention concerne une composition renfermant une quantité efficace d'anticorps 8H9 monoclonaux ou d'un dérivé de ceux-ci et un excipient approprié. L'invention concerne une composition pharmaceutique renfermant une quantité efficace d'anticorps 8H9 monoclonaux ou d'un dérivé de ceux-ci et un excipient acceptable sur le plan pharmaceutique. L'invention concerne en outre un anticorps différent de l'anticorps 8H9 monoclonal, renfermant les régions de détermination complémentaires de l'anticorps 8H9 monoclonal ou d'un dérivé de celui-ci et capable de se lier au même antigène que l'anticorps 8H9 monoclonal. L'invention concerne aussi une substance capable d'inhiber de manière compétitive la liaison d'anticorps 8H9 monoclonaux; ainsi un scFv isolé d'anticorps 8H9 monoclonaux ou d'un dérivé de ceux-ci et l'antigène 8H9. L'invention concerne enfin différentes utilisations de l'anticorps 8H9 monoclonal ou de son dérivé.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/097,558 | 2002-03-08 | ||
US10/097,558 US7737258B2 (en) | 2000-10-18 | 2002-03-08 | Uses of monoclonal antibody 8H9 |
PCT/US2002/033331 WO2003033670A2 (fr) | 2001-10-17 | 2002-10-17 | Procede de preparation d'anticorps monocatenaires |
US10/273,762 | 2002-10-17 | ||
US10/273,762 US7666424B2 (en) | 2001-10-17 | 2002-10-17 | Methods of preparing and using single chain anti-tumor antibodies |
USPCT/US02/33331 | 2002-10-17 | ||
PCT/US2003/007004 WO2003075846A2 (fr) | 2002-03-08 | 2003-03-06 | Utilisations d'anticorps 8h9 monoclonaux |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2478082A1 CA2478082A1 (fr) | 2003-09-18 |
CA2478082C true CA2478082C (fr) | 2016-02-02 |
Family
ID=27808456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2478082A Expired - Lifetime CA2478082C (fr) | 2002-03-08 | 2003-03-06 | Utilisations d'anticorps 8h9 monoclonaux |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003220079A1 (fr) |
CA (1) | CA2478082C (fr) |
WO (1) | WO2003075846A2 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7740845B2 (en) | 2000-10-18 | 2010-06-22 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US7737258B2 (en) | 2000-10-18 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US8414892B2 (en) | 2000-10-18 | 2013-04-09 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US8501471B2 (en) | 2000-10-18 | 2013-08-06 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
AU2003298794A1 (en) * | 2002-12-02 | 2004-06-23 | Us Gov Health & Human Serv | Recombinant immunotoxin and use in treating tumors |
EP2937360A1 (fr) | 2005-06-17 | 2015-10-28 | Merck Sharp & Dohme Corp. | Molécules se liant à l'ilt3 et leurs utilisations |
JP5597793B2 (ja) * | 2006-06-19 | 2014-10-01 | メルク・シャープ・アンド・ドーム・コーポレーション | Ilt3結合分子およびその使用 |
EP2121008A4 (fr) * | 2007-03-22 | 2010-03-31 | Sloan Kettering Inst Cancer | Utilisations de l'anticorps monoclonal 8h9 |
CA2826942C (fr) | 2011-02-11 | 2021-08-03 | Memorial Sloan-Kettering Cancer Center | Proteines de liaison a l'antigene specifiques d'un peptide a restriction hla |
PE20141271A1 (es) | 2011-04-01 | 2014-10-08 | Sloan Kettering Inst Cancer | Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2 |
US10865245B2 (en) | 2014-12-23 | 2020-12-15 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
WO2016106004A1 (fr) | 2014-12-23 | 2016-06-30 | Full Spectrum Genetics, Inc. | Nouveaux composés de liaison anti-b7h3 et leurs utilisations |
EP3806848A2 (fr) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V, Inc. | Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires |
MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
EP4022313A1 (fr) | 2019-08-30 | 2022-07-06 | Y-Mabs Therapeutics, Inc. | Évaluation immunohistochimique de l'expression de b7-h3 |
JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
JP2024512669A (ja) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用 |
WO2023278641A1 (fr) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Cellules immunitaires modifiées pour favoriser la thanotransmission de phényléthanolamines et leurs utilisations |
WO2024077191A1 (fr) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer |
-
2003
- 2003-03-06 AU AU2003220079A patent/AU2003220079A1/en not_active Abandoned
- 2003-03-06 WO PCT/US2003/007004 patent/WO2003075846A2/fr not_active Application Discontinuation
- 2003-03-06 CA CA2478082A patent/CA2478082C/fr not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU2003220079A8 (en) | 2003-09-22 |
CA2478082A1 (fr) | 2003-09-18 |
AU2003220079A1 (en) | 2003-09-22 |
WO2003075846A2 (fr) | 2003-09-18 |
WO2003075846A3 (fr) | 2005-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9938351B2 (en) | Uses of monoclonal antibody 8H9 | |
US9062110B2 (en) | Uses of monoclonial antibody 8H9 | |
EP1572077B1 (fr) | Utilisations d'anticorps 8h9 monoclonaux | |
US20020102264A1 (en) | Uses of monoclonal antibody 8H9 | |
CA2478082C (fr) | Utilisations d'anticorps 8h9 monoclonaux | |
WO2002032375A9 (fr) | Utilisations d'anticorps monoclonal 8h9 | |
US7740845B2 (en) | Uses of monoclonal antibody 8H9 | |
Modak et al. | Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors | |
Caron et al. | Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies | |
Mehren et al. | Monoclonal antibody therapy for cancer | |
Lutterbuese et al. | Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA | |
US8148154B2 (en) | Method for preparation of single chain antibodies | |
US20040115205A1 (en) | Use of antibodies against the MUC18 antigen | |
US20030147809A1 (en) | Antibodies against the MUC18 antigen | |
US20030152514A1 (en) | Methods for using anti-MUC18 antibodies | |
US20040018198A1 (en) | Antibodies against carbonic anydrase IX (CA IX) tumor antigen | |
HUE031151T2 (en) | Pharmaceutical compositions resistant to soluble CEA | |
US20070237761A1 (en) | Chimeric Anti Cd44 Antibodies and Their Use for Treating Acute Myeloid Leukemia | |
KR20220007873A (ko) | 뮤신-16에 대한 인간화된 항체 및 이의 사용 방법 | |
Mount et al. | Chimeric (mouse/human) anti-colon cancer antibody c30. 6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice | |
Krauss | Recombinant antibodies for the diagnosis and treatment of cancer | |
Cheung et al. | Methods of preparing and using single chain anti-tumor antibodies | |
Krauss et al. | Application of recombinant antibodies in cancer patients | |
Cheung et al. | Method for preparation of single chain antibodies | |
Goel et al. | Antibody constructs for radioimmunodiagnosis and treatment of human pancreatic cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20150716 |
|
FZDC | Discontinued application reinstated |
Effective date: 20151110 |
|
MKEX | Expiry |
Effective date: 20230306 |